Omalizumab, a recombinant humanized IgG1 monoclonal antibody directed against IgE, is now recommended as add-on therapy in those with severe asthma who remain uncontrolled on high-dose inhaled corticosteroids and long-acting bronchodilators. This evidence concerns the gene IGHE and asthma.